Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes

被引:0
作者
Elza Muscelli
Brenno Astiarraga
Elisabetta Barsotti
Andrea Mari
Freimut Schliess
Leszek Nosek
Tim Heise
Uli C. Broedl
Hans-Juergen Woerle
Ele Ferrannini
机构
[1] University of Pisa,Department of Clinical and Experimental Medicine
[2] C.N.R. Institute of Neuroscience,undefined
[3] Profil,undefined
[4] Boehringer Ingelheim Pharma GmbH & Co. KG,undefined
[5] CNR Institute of Clinical Physiology,undefined
来源
Diabetologia | 2016年 / 59卷
关键词
Empagliflozin; Endogenous glucose production; Glycosuria; Metformin; Type 2 diabetes;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:700 / 708
页数:8
相关论文
共 103 条
[1]  
Wright EM(2011)Biology of human sodium glucose transporters Physiol Rev 91 733-794
[2]  
Loo DD(2011)Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2 Am J Physiol Cell Physiol 300 C14-C21
[3]  
Hirayama BA(2011)SGLT2 mediates glucose reabsorption in the early proximal tubule J Am Soc Nephrol 22 104-112
[4]  
Hummel CS(2014)Ipragliflozin: first global approval Drugs 74 611-617
[5]  
Lu C(2014)Tofogliflozin: first global approval Drugs 74 939-944
[6]  
Loo DD(2014)Luseogliflozin: first global approval Drugs 74 945-950
[7]  
Hirayama BA(2012)LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial Clin Pharmacol Ther 92 158-169
[8]  
Voss AA(2015)Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin Diabetes Obes Metab 17 591-598
[9]  
Wright EM(2015)Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes Diabetes Obes Metab 17 98-101
[10]  
Vallon V(2012)SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects Nat Rev Endocrinol 8 495-502